Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ATR
Variant I774fs
Impact List frameshift
Protein Effect loss of function - predicted
Gene Variant Descriptions ATR I774fs results in a change in the amino acid sequence of the Atr protein beginning at aa 774 of 2644, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the PI3K/PI4K domain and the FATC domain (UniProt.org), I774fs is predicted to lead to a loss of Atr protein function.
Associated Drug Resistance
Category Variants Paths

ATR mutant ATR inact mut ATR I774fs

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_001184.4
gDNA chr3:g.(142555898_142555899)
cDNA c.(2320_2319)
Protein p.I774fs
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_047448362.1 chr3:g.(142555898_142555899) c.(2320_2319) p.I774fs RefSeq GRCh38/hg38
XM_011512924 chr3:g.(142555898_142555899) c.(2320_2319) p.I774fs RefSeq GRCh38/hg38
XM_047448361.1 chr3:g.(142555898_142555899) c.(2320_2319) p.I774fs RefSeq GRCh38/hg38
XM_011512926 chr3:g.(142555898_142555899) c.(2320_2319) p.I774fs RefSeq GRCh38/hg38
NM_001184.4 chr3:g.(142555898_142555899) c.(2320_2319) p.I774fs RefSeq GRCh38/hg38
NM_001184.3 chr3:g.(142555898_142555899) c.(2320_2319) p.I774fs RefSeq GRCh38/hg38
XM_047448364.1 chr3:g.(142555898_142555899) c.(2320_2319) p.I774fs RefSeq GRCh38/hg38
XM_011512924.2 chr3:g.(142555898_142555899) c.(2320_2319) p.I774fs RefSeq GRCh38/hg38
XM_047448360.1 chr3:g.(142555898_142555899) c.(2320_2319) p.I774fs RefSeq GRCh38/hg38
XM_011512924.1 chr3:g.(142555898_142555899) c.(2320_2319) p.I774fs RefSeq GRCh38/hg38
XM_047448363.1 chr3:g.(142555898_142555899) c.(2320_2319) p.I774fs RefSeq GRCh38/hg38
NM_001184 chr3:g.(142555898_142555899) c.(2320_2319) p.I774fs RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ATR inact mut prostate cancer sensitive Enzalutamide + Talazoparib Guideline Actionable Talzenna (talazoparib) plus Xtandi (enzalutamide) is included in guidelines as systemic therapy for patients with metastatic castration-resistant prostate cancer harboring a pathogenic germline or somatic ATR mutation who have not been treated in the setting of castration-resistant prostate cancer (NCCN.org). detail...
ATR inact mut prostate cancer sensitive Enzalutamide + Talazoparib FDA approved Actionable In a Phase III trial (TALAPRO-2) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median radiographic progression-free survival compared to enzalutamide plus placebo (27.9 vs 16.4 mo, HR 0.46, p=0.0003) in patients with metastatic castration-resistant prostate cancer harboring deficient homologous recombination repair genes including ATR, with an HR of 0.66 (p=0.12) in patients with non-BRCA mutations treated with Talzenna (talazoparib) (PMID: 37285865; NCT03395197). detail... 37285865